Tag: Checkpoint Inhibitors
Neutrophil Defensin Expression Correlated With Immune Checkpoint Response In Lung Cancer
Lung cancer is the leading cause of cancer related death. Non-small cell lung cancer (NSCLC), comprises 80–85% of all lung cancer cases. Programmed cell death ligand 1 (PDL1) is an approved immunotherapeutic target in lung cancer patients. PDL1 expression...
CLOVER Study Of PDL1 In NSCLC Demonstrates PCR RNA Expression Analysis Not Equivalent To...
Programmed cell death ligand 1 (PDL1) is approved therapeutic target in lung cancer patients. PDL1 expression above a set threshold must be confirmed by companion immunohistochemistry (IHC) test in order for the patient to be eligible for PDL1 checkpoint...
